The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a problem not yet solved same for all drug-eluting stents. The Absorb (Abbott Vascular, Abbott Park, IL, USA) is the first absorbable vascular support approved for clinical use. The EVERBIO II study<a href="https://solaci.org/en/2015/06/24/everbio-ii-bio-absorbable-stent-absorb-versus-everolimus-eluting-or-biolimus-stents/" title="Read more" >...</a>

There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination of anticoagulants, aspirin, and clopidogrel greatly increases the rate of bleeding, because of this, the time of the triple scheme should be as short as possible.&nbsp; The aim of this study was to compare the triple therapy for<a href="https://solaci.org/en/2015/06/24/isar-triple-6-weeks-versus-6-months-of-clopidogrel-in-patients-with-oral-anticoagulation-and-drug-eluting-stent/" title="Read more" >...</a>

This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction<a href="https://solaci.org/en/2015/06/24/ribs-iv-drug-eluting-balloon-versus-everolimus-eluting-stent-on-in-stent-restenosis/" title="Read more" >...</a>

This multicenter work from Japanrandomized 3200 patients to receive biodegradable polymer biolimus eluting stent(Nobori) or everolimus-eluting stent with permanent polymer (Xience / Promus). The primary end point for efficacy was any revascularizationlesion. A two year follow up the Nobori stent was non-inferior to death or myocardial infarction (7.83% versus 7.69%) and TLR (6.23% versus 5.95%).&nbsp;<a href="https://solaci.org/en/2015/06/24/next-trial-biodegradable-polymer-stent-nobori-was-similar-to-the-permanent-polymer-stents-xience-promus-at-2-years/" title="Read more" >...</a>

The use of drug-eluting stents versus bare metal stents is controversial in some clinical situations in patients at high risk of bleeding.This study randomized 1606 patients considered at low risk of restenosis but with high risk of bleeding receiving Zotarolimus eluting stent (Endeavor) or conventional stent.The clinical characteristics were similar between the two groups with<a href="https://solaci.org/en/2015/06/24/zeus-trial-patients-with-increased-risk-of-bleeding-may-benefit-from-eluting-stents-zotarolimus/" title="Read more" >...</a>

Summary: Second-generation drug-eluting stents have shown better results than their predecessors. In this study we compare two second-generation drug stents in patients with unprotected left coronary trunk injuries. Methods and results: 650 patients with unprotected trunk injury were randomized to either XIENCE V (everolimus eluting) or RESOLUTE (zotarolimus eluting) stents. The primary endpoint was the<a href="https://solaci.org/en/2015/06/24/isar-left-main-2-everolimus-eluting-stents-versus-zotarolimus-eluting-stents-in-the-treatment-of-the-unprotected-left-coronary-trunk/" title="Read more" >...</a>

Drug-eluting balloons could reduce intimal hyperplasia detected by OCT in intmerventions with conventional stents. 30 patients were randomized into 3 groups: 10 patients received conventional stents, 10 patients received a drug-eluting balloon prior to the conventional stent, and 10 patients receive a drug-eluting balloon after the conventional stent. We performed angiographic and OCT follow-up at<a href="https://solaci.org/en/2015/06/24/in-pact-coro-oct-validation-of-drug-eluting-balloons/" title="Read more" >...</a>

The ideal therapy for treating in-stent restenosis continues to be debated . The pharmacological balloons showed good results in this context, but no direct comparisons available of pharmacological balloonsversus second-generation DES.This prospective, multicenter randomized 189 patients with in-stent restenosis of conventional stents receiving pharmacological balloon or everolimusDES.The primary endpoint was angiographicat 9 months spotting a<a href="https://solaci.org/en/2015/06/24/ribs-v-pharmacological-balloon-vs-second-generation-drug-eluting-stent-in-the-treatment-of-bms-restenosis/" title="Read more" >...</a>